SM03 + methotrexate

A combination therapy consisting of **SM03** and **methotrexate**. Methotrexate is a well-established conventional synthetic disease-modifying antirheumatic drug (csDMARD) that inhibits dihydrofolate reductase, interfering with DNA synthesis and cell proliferation, especially in rapidly dividing immune cells. It is widely used to treat **rheumatoid arthritis** (RA) and other autoimmune diseases. SM03 appears to be a code name, likely for an investigational drug or monoclonal antibody, but there is insufficient publicly available information to precisely identify its mechanism, target, or developer. The combination is likely aimed at improving disease control in patients with autoimmune or inflammatory diseases, potentially by targeting different aspects of the immune response.

Other names

methotrexate